Mitsubishi Tanabe licenses Menarini to sell Spedra in 10 Asia-Pac countries

27 February 2016

Japanese drugmaker Mitsubishi Tanabe Pharma (TYO: 4508) and the Singapore-based subsidiary of Italian pharma company Menarini have entered into a licensing agreement to commercialize and promote Spedra (avanafil).

Menarini Asia-Pacific AP will receive exclusive licensing rights from Mitsubishi Tanabe to market the erectile dysfunction drug avanafil in China, Hong Kong, Macao, Taiwan, Indonesia, Malaysia, Philippines, Singapore, Thailand and Vietnam. The Menarini Group has already been licensed to market this product in over 40 European countries, plus Australia and New Zealand, under a license from the drug’s originator, US drugmaker Vivus (Nasdaq: VVUS).

Spedra is a new and innovative phosphodiesterase – 5 inhibitor (PDE5-i) approved by the European Commission in June 2013 for the treatment of erectile dysfunction. In the USA, the Food and Drug Administration approved avanafil in April 2012 for the same indication, under the trade name Stendra.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK